Thursday, August 10, 2023
Marinomed Biotech forms long-term Solv4U technology partnership with SPH Sinae Pharmaceutical Laboratories.
Marinomed's Solv4U technology partnerships will address challenges related to solubility and bioavailability, thus bolstering API formulation development during the crucial stages of drug discovery and early development.
The alliance between Marinomed and SPH Sinae holds immense promise for the future. Both entities will jointly file a patent for the innovative product resulting from their synergistic efforts.
SPH Sinae will make use of Marinosolv Technology for active pharmaceutical ingredients (APIs) dissolution in orally inhaled and nasal drug products. The partnership with SPH Sinae serves as a compelling catalyst for Marinomed to enhance its commitment towards furthering and broadening the Solv4U platform.
This collaboration represents a strategic move towards leveraging Solv4U's clinically proven technology to enhance the development of more efficacious and sustainable pharmaceuticals for the ultimate benefit of patients.
